The 2027 sponsor and exhibitor list is not published yet (the organizer’s page still shows last year’s). We’ll add the exhibitors and their booths when it is, along with new sessions as the agenda fills in.

Biotech companies at BPI West 2027

Mar 16–18, 2027 San Diego, CA ~800 attendees Website

9 biotech companies are at BPI West 2027 — 9 presentations on the program. Most represented: Abalos Therapeutics (1 on the program), Arcturus Therapeutics (1 on the program), BlueRock Therapeutics (1 on the program). As of Oct 15, 2026.

All 41 organizations at BPI West 2027 →

Showing 1–9 of 9 organizations

Organization	BPI West 2027 Attendance
Abalos Therapeutics Düsseldorf, Germany
abalos-tx.com Biotech Clinical-stage oncology company developing systemically delivered, arenavirus-based immunotherapies that trigger innate and adaptive immune responses against solid tumors.	Talk Thu Mar 18 4:45pm–5:15pm From Innovation to the Clinic: Navigating the Challenges of Platform Manufacturing for Arenavirus-Based Cancer Immunotherapies Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production
Arcturus Therapeutics San Diego, California
arcturusrx.com Biotech Develops self-amplifying mRNA vaccines and mRNA medicines, including a self-amplifying COVID-19 vaccine approved in Japan and Europe.	Panel Thu Mar 18 10:00am–10:30am Panel Discussion: Supply Chain, Data Governance, and the End-to-End Value Chain for Advanced Therapies Why patient-specific therapies need a supply chain run on clear data, with each dose's identity and handling traced from start to finish.
BlueRock Therapeutics Cambridge, Massachusetts
bluerocktx.com Biotech Bayer subsidiary developing pluripotent stem cell-derived cell therapies, including a Parkinson's disease program.	Talk Wed Mar 17 11:15am–11:45am Not Every Opportunity is a Priority: Strategic Process Development at BlueRock How to judge which process changes are worth their cost, matching effort to each program's stage and planning backward from a commercial process.
Denali Therapeutics South San Francisco, California
denalitherapeutics.com Biotech Develops medicines for neurodegenerative and lysosomal diseases, using its Transport Vehicle platform to carry biologics across the blood-brain barrier.	Talk Thu Mar 18 10:00am–10:30am Cell Line Development & Engineering: title to be announced
KiraGen Bio Boston, Massachusetts
kiragenbio.com Biotech Preclinical company developing multiplex base-edited, healthy-donor CAR-T cell therapies for solid tumors, starting with recurrent glioblastoma.	Talk Thu Mar 18 4:15pm–4:45pm Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production: title to be announced
Ottimo Pharma
ottimopharma.com Biotech Clinical-stage biotech developing bifunctional antibodies for cancer, led by a dual-paratopic PD-1/VEGFR2 antibody.	Talk Wed Mar 17 9:00am–9:30am Fast to Clinic, Fast to Launch: Record Breaking Speed to the Patient Taking a drug from chosen molecule to first patient in 12 months and launch-ready manufacturing in under 5 years with several contract manufacturers.
Sangamo Therapeutics
sangamo.com Biotech Genomic medicine company developing gene therapies and zinc finger-based genome regulation for neurological diseases.	Talk Wed Mar 17 2:00pm–2:30pm Innovating Within Control: A CMC Strategy for Regulatory Readiness for AAV based therapies Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production
Ultragenyx Novato, California
ultragenyx.com Biotech Develops and commercializes therapies for rare and ultra-rare genetic diseases, including AAV gene therapies.	Talk Thu Mar 18 2:30pm–3:00pm Next-Gen Modality, Cell Therapy, and Gene Therapy Development & Production: title to be announced
VT Vita Therapeutics Baltimore, Maryland
Biotech Cell therapy company developing induced pluripotent stem cell-derived muscle stem cell therapies for muscular dystrophies, led by a limb-girdle program.	Talk Wed Mar 17 4:15pm–4:45pm Innovating Within Control: A CMC Strategy for Regulatory Readiness for AAV based therapies How gene therapies carried by adeno-associated virus get ready for regulators, from FDA fast-track options to proving process changes leave the product unchanged.